Waiting for the approval of FDA on new impotence medication

Avanafil, a relatively new erectile dysfunction drug, manufactured by VIVUS Inc has been submitted to the United States FDA (Food and Drug Administration)

The Medication has been run through a number clinical trials and tests and has shown to be both efficient and safe. The idea behind submitting this new medication is that it could possibly be a profitable alternative to many of the leading and known erectile dysfunction drugs (Viagra, Cialis and Levitra)

The third phase of the clincal trials, consisting of 1350 test subjects, has been completed. It was seen that within fifteen minutes the medication begins to work with minimal side effects.

The new drug Avanafil is a PDE-5 inhibitor, much like its counterparts, Viagra, Cialis and Levitra. A PDE-5 inhibitor is known for the treatment of erectile dysfunction by preventing cyclic GMP being broken down too quickly by the PDE-5 Enzyme. If Vivus's Avanafil is approved, they will be entering a major drug market valued worldwide at around $4 billion.

The erectile dysfunction market is becoming extremeley competitive and with Viagra's patent expiring in 2012, Avanafil could be a game changer within the drug market.